Compare · MRK vs OGI
MRK vs OGI
Side-by-side comparison of Merck & Company Inc. (MRK) and Organigram Global Inc. (OGI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and OGI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $298.33B, about 1999.2x OGI ($149.2M).
- Over the past year, MRK is up 50.7% and OGI is down 22.0% - MRK leads by 72.7 points.
- MRK has hit the wire 26 times in the past 4 weeks while OGI has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 7 for OGI).
- Company
- Merck & Company Inc.
- Organigram Global Inc.
- Price
- $119.49-1.15%
- $1.08+1.41%
- Market cap
- $298.33B
- $149.2M
- 1M return
- +6.40%
- -22.02%
- 1Y return
- +50.70%
- -22.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 7
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Organigram Global Inc.
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Latest MRK
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
- SEC Form 4 filed by Director Lavizzo-Mourey Risa J
Latest OGI
- Europe's Cannabis Boom Is Accelerating as Billions Flow into Licensed Markets
- SEC Form 6-K filed by Organigram Global Inc.
- Organigram Reports Second Quarter Fiscal 2026 Results
- SEC Form 6-K filed by Organigram Global Inc.
- Organigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026
- SEC Form 6-K filed by Organigram Global Inc.
- Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities
- SEC Form 6-K filed by Organigram Global Inc.
- Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting
- SEC Form 6-K filed by Organigram Global Inc.